A number of small molecule tyrosine kinase inhibitors (TKIs) have now been approved for the treatment of non-small cell lung cancers (NSCLC), including those targeted against epidermal growth factor receptor, anaplastic lymphoma kinase, and ROS1. Despite a wealth of agents developed to target the receptor tyrosine kinase, MET, clinical outcomes have as yet been disappointing, leading to pessimism about the role of MET in the pathogenesis of NSCLC. However, in recent years, there has been a renewed interest in MET exon 14 alterations as potential drivers of lung cancer.
Introduction (the Why)
Orally available small molecule tyrosine kinase inhibitors (TKIs) have now been approved for epidermal growth factor receptor (EGFR)-mutated, anaplastic lymphoma kinase (ALK)-rearranged, and ROS1-rearranged non-small cell lung cancers (NSCLC), altering the treatment landscape of NSCLC [1] . Alterations (point mutations, amplifications, protein overexpression, and fusions) in another receptor tyrosine kinase (RTK), the hepatocyte growth factor (HGF) receptor (MET), have been identified in NSCLC, and a plethora of MET-targeted agents (small molecular TKIs and antibodies against HGF or MET) have been investigated in this disease type [2] . Disappointingly, despite the wide spectrum of MET alterations in NSCLC, randomized trials with MET inhibitors have not resulted in clinical benefit [3] [4] [5] . These disappointing results have led to pessimism about the role of MET in the pathogenesis of NSCLC and the validity of MET as a targetable driver in NSCLC. This review will concentrate on the recent re-emergence of MET exon 14 (METex14) splicing alterations in NSCLC that has led to renewed optimism of METex14 alteration as a targetable mutation that may lead to the approval of MET-specific inhibitors in NSCLC.
METex14 splicing mutations in NSCLC
The MET signaling pathway has recently been reviewed in detail [6] . The timeline of events leading to the recognition of METex14 alteration as an important driver in lung cancer is summarized in Fig. 1 . In 1994, an alternatively spliced MET RTK with deletion of the 47-amino acid juxtamembrane region of the MET receptor was reported [7] , followed by the demonstration that mutation of a tyrosine residue at position 1001 in this juxtamembrane region led to a partial gain of function [8] . In 2001, Peschard and colleagues reported that mutation of tyrosine residue 1003 in the binding domain of the E3 ubiquitin-protein ligase, c-CBL, abolished c-CBL binding to MET, disrupting c-CBL-mediated degradation and leading to MET oncogenic activity [9] . Y1003 is located in the juxtamembrane region of MET and is encoded by exon 14 [6] . Subsequently, mutations in the METex14 splice sites were reported by Ma and colleagues in small cell lung cancer in 2003 and NSCLC in 2005 [10, 11] . The significance of these splice site mutations was further characterized by Kong-Beltran and colleagues in 2006, when they identified both single nucleotide substitutions and small deletions in the 5 and 3 splice sites around METex14 in lung tumor samples, and demonstrated that these mutations resulted in METex14 skipping. The exon 14-spliced protein had abolished c-CBL E3 ligase binding, resulting in decreased ubiquitination, and leading to a relative increase in MET protein levels. Additionally, MET Y1003 mutation was shown to result in decreased ubiquitination and increased stability of the MET protein. Both METex14-spliced and MET Y1003-mutated proteins were transforming in vitro and in a xenograft model that was inhibited by an anti-MET antibody [12] . Since then, sporadic case series have reported the incidence of METex14 alterations in NSCLC to be around 2-4% [13] [14] [15] . It was not until 2015 that large scale molecular profiling of METex14 alterations in 38,028 tumor samples by Frampton and colleagues led to renewed focus on METex14 alterations in lung carcinomas [16] . Among the 221 tumor samples harboring METex14 alterations, 193 were in lung carcinomas, including 131 lung adenocarcinoma samples. No other common solid tumor malignancies harbored METex14 alterations to the same degree as lung neoplasms [16] . Furthermore, in 2015, an in vitro model using the CRISPR/Cas9 system in HEK293 cell lines demonstrated that METex14 deletion resulted in higher MET protein expression levels, enhanced MET phosphorylation, prolonged MET activation, and enhanced cellular growth, colony formation, and MET inhibitor sensitivity [17] . Contemporaneously, case reports and case series have reported that patients with METex14 altered NSCLC (METex14+ NSCLC) respond to MET TKIs [18] [19] [20] [21] [22] .
Since late 2015, reports characterizing patients with METex14+ NSCLC have been published in rapid succession in the literature (Table 1) [16, [23] [24] [25] [26] [27] [28] [29] [30] [31] . To date, it can be summarized that METex14 alterations are found in a relatively elderly population of patients with NSCLC, and are enriched in sarcomatoid histologies, with a prevalence ranging from 8 to 22% [25, 31] . On average, METex14 alterations occurred at a prevalence of about 3% in lung adenocarcinoma, and notably, at a prevalence of slightly higher than 2% in squamous cell carcinoma (SqCC) [31] . Available data on the overlap between METex14 alterations, MET amplification, and MET point mutations are sparse, but concurrent MET amplification has been reported in 15-21% of METex14+ NSCLC [24, 26, 31] , and MET Y1003X mutations account for around 2% of the METex14 alterations in NSCLC [31] . Based on 28 patients, Awad and colleagues showed that Stage IV METex14-mutated NSCLCs were significantly more likely to have concurrent MET genomic amplification and strong MET immunohistochemical expression than stage IA to IIIB METex14-mutated NSCLCs [24] . However, a much larger series of 298 METex14+ patients did not show the correlation between MET amplification and advanced stage [31] .
Clinical trial design considerations of a MET TKI trial targeting METex14+ NSCLC (the How)
There are several MET TKIs in development that target METex14+ NSCLC, and completing accrual as soon as possible is of paramount importance given the relatively low incidence of METex14+ NSCLC. Eligibility criteria for MET TKI trials in METex14+ NSCLC should thus be tailored to allow speedy accrual. From the report of Schrock and colleagues, METex14 alterations occur in approximately 2% of patients with SqCC [31] , and these patients have been shown to respond to MET TKIs [16, 27, 31] . Therefore, it is advised to include both major histologies (adenocarcinoma and SqCC) in addition to sarcomatoid lung cancer.
It is generally accepted that in NSCLC with a validated targetable driver mutation, highly effective targeted therapy should work regardless of prior lines of chemotherapy. For example, a phase 2 study of crizotinib in ROS1 inhibitor-naïve ROS1+ NSCLC patients revealed no difference in the overall response rate (ORR) whether patients were treatment naïve or had received more than three prior chemotherapy regimens [32] . Thus, a clinical trial of MET TKIs in METex14+ NSCLC patients should allow any prior lines of therapy (chemotherapy or immunotherapy). Indeed, the recently presented phase 2 trial of crizotinib in METex14+ NSCLC patients allowed both treatment-naïve and chemotherapy-refractory patients [33] .
Finally, a sensitive, reliable, and rapid molecular test that can be easily performed in diagnostics laboratories should be incorporated into MET TKI trials, for the purpose of getting a compendium of diagnostics for METex14 alterations approved. As shown in Table 1 , most of the methods used to detect METex14 alterations, including MET Y1003 mutation, are based on DNA sequencing. Thus, the actual results of METex14 skipping are inferred from the substitutions and indels observed at the splice donor and acceptor sites. As demonstrated by The Cancer Genome Atlas (TCGA) analysis of adenocarcinoma, some of the METex14 alterations detected at the DNA level resulted in incomplete (80%) METex14 skipping [14] . Thus, confirmation of actual METex14 skipping by differential MET exon expression [15, 21] , quantitative reverse transcriptase-polymerase chain reaction (qRT-PCR) [24] , or direct RNA sequencing [15, 27] should be part of the test for METex14 alterations. Additionally, both DNA and RNA sequencing methods will be needed to detect Y1003, the "functional analog" of METex14 skipping alterations, which accounts for approximately 2% of all METex14 alterations [31] .
MET TKI in METex14 skipping alterations in NSCLC (the Who)
Multiple MET inhibitors, including both small molecule TKIs and monoclonal antibodies (mAbs) against MET or its ligand, HGF, have been in clinical development since the early 2000 s [34] . TKIs can generally be divided into three types (I, II, and III) [35, 36] . The binding of ATP to the MET kinase domain has been succinctly reviewed by Gherardi and colleagues [35] . The apo-MET kinase adopts a unique autoinhibitory conformation with the activation loop locked into the ATP triphosphate binding site via a salt bridge between D1228 and K1110. Type I MET-inhibitors are ATP-competitive, and bind to this MET unique autoinhibitory conformation with characteristic interaction (-stacking) with Y1230 in the MET activation loop. Type I inhibitors can be further divided into two types: type Ia and type Ib. The potency of type Ia inhibitors comes from interaction with Y1230, the hinge, and the solvent front glycine residue G1163 (analogous to the same position as ALK G1202 and ROS1 G2032), whereas type Ib series have stronger interactions with Y1230 and the hinge, but normally no interaction with G1163. Type Ib inhibitors are highly specific for MET with fewer off target effects as compared with type Ia inhibitors. Type II inhibitors are also ATP-competitive, but bind to the ATP adenine binding site and extend to the hydrophobic back pocket. As such, type II inhibitors generally distort the apo-MET autoinhibitory conformation and bind to an induced conformation with a certain penalty; potency depends on the activation state of the MET protein. Normally, there is no interaction with the solvent front residue G1163; thus, type II inhibitors could potentially rescue solvent front mutations. However, as type II inhibitors occupy the induced back [38] [39] [40] . In MET-dependent cancer cell lines, crizotinib inhibits autophosphorylation of MET, which in turn leads to inhibition of signal transduction and cell proliferation, and induction of apoptosis [38, 41] .
In August 2011, crizotinib was approved for the treatment of ALK-rearranged NSCLC [42] , and in March 2016, was approved for treatment of ROS1-rearranged NSCLC by the US Food and Drug Administration (FDA) [43] . Crizotinib has also demonstrated clinical activity in NSCLC with MET amplification, especially among patients with high MET amplification, proving it is a bona fide MET inhibitor [40, 44] . Preliminary results were recently presented from the PROFILE-1001 study in which 21 treatment-naïve or chemotherapy-refractory METex14+ NSCLC patients were enrolled, 18 of which were evaluable at the time of presentation. Within a relatively short 5.3 months of median follow-up time, the ORR was 44% [33] . Additionally, crizotinib is the TKI for the METex14 arms of two large phase 2 basket trials; the NCI-MATCH trial (NCT02465060) in the US and the National Lung Matrix trial (NCT02664935) in the UK, for patients with METex14+ solid malignancies and lung cancer respectively [45, 46] . A phase 2 trial, the METROS study, is ongoing in pretreated patients with metastatic NSCLC with MET or ROS aberrations (Table 2 ) [45] . With the safety data of crizotinib firmly established, it is likely that crizotinib will be the first MET TKI to receive FDA approval for METex14+ NSCLC in the near future.
Type Ib inhibitors

Capmatinib (INC280)
Capmatinib (INC280; Novartis) is also an oral, ATP-competitive, type Ib MET inhibitor. It has extremely potent inhibitory activity against MET, with a cellular kinase IC 50 of 0.13 nM, and a cell-based IC 50 of 0.4-0.7 nM (Table 1) [47] . Capmatinib inhibits signaling pathways and cell proliferation, induces apoptosis in MET-dependent cell lines, and demonstrates single-agent antitumor activity in MET-driven mouse xenograft models [47] . The efficacy and safety of capmatinib as a single agent were investigated in a phase 1 study in patients with advanced solid tumors, including a cohort of EGFR-wild-type MET+ (mutated, amplified, or rearranged) NSCLC patients (N = 55). The drug was well tolerated, with no grade 3/4 adverse events occurring in over 10% of patients, and preliminary activity was observed in NSCLC patients with high MET gene copy number (GCN) ≥6 or MET overexpression as measured by immunohistochemistry (IHC 3 +), with an ORR of 47% and 24%, respectively [48] . Four METex14+ NSCLC patients were enrolled and all achieved significant reductions in tumor volume (>45%) [22, 48] . A phase 2 trial of capmatinib that includes a study arm investigating its clinical efficacy in METex14+ NSCLC patients is currently ongoing (GEOMETRY mono-1) [45] . There is also an investigator-initiated phase 2 study of capmatinib in patients with METex14+ NSCLC who have received a prior MET inhibitor (Table 2 ) [45] . Furthermore, capmatinib has been investigated in combination with gefitinib in patients with EGFR-mutated NSCLC, and acquired MET amplification as a resistance mechanism to EGFR inhibitors; the ORR was 50% in patients with MET GCN ≥6 [49] . A phase 2 study (GEOME-TRY duo-1) is ongoing for this clinical setting, in combination with erlotinib [50] .
Tepotinib (MSC2156119J, EMD 1214063)
Tepotinib (EMD1214063, MSC2156119J; Merck) is another oral, ATP-competitive, and highly selective MET inhibitor [51] . Preclinical antitumor activity was observed in a number of murine xenograft models of human tumors, including in the ligand-independent, MET-amplified EBC-1 NSCLC model. Antitumor activity was also seen in other non-lung tumor models, regardless of whether MET activation was HGF dependent or independent [51] .
The efficacy and safety of tepotinib was assessed in a phase 1 single-agent study in patients with solid tumors, including NSCLC. Tepotinib was well tolerated and showed antitumor activity, especially in patients with overexpressed or amplified MET [52] . A phase 2 trial investigating the activity of tepotinib in METex14+ NSCLC patients has been initiated (Table 2 ) [45, 53] 
Savolitinib (AZD6094, volitinib, HMPL-504)
Savolitinib (AZD6094, volitinib, HMPL-504; AstraZeneca) is an orally available inhibitor, with potent, selective activity against MET [54] . In preclinical studies, savolitinib inhibited phosphorylation of MET and downstream signaling, and had antitumor activity against a number of xenograft models, including those of EGFR-and KRAS-wild-type NSCLC [55] . The safety and efficacy of savolitinib as a single agent was investigated in a phase 1 study in patients with solid tumors, including NSCLC. The drug was well tolerated, and preliminary antitumor activity was observed [56] . Savolitinib has also demonstrated inhibitory activity against METex14 alterations and MET Y1003 mutations in cell lines with acquired resistance to savolitinib mediated by MYC overexpression [57] . A phase 2 trial of savolitinib in patients with METex14+ positive pulmonary sarcomatoid carcinoma has recently been initiated in China (Table 2) [45].
AMG-337
AMG337 (Amgen, Nanbio) is another highly selective, orally available ATP-competitive MET inhibitor [58] . In a phase 1/2 trial of esophageal, gastro-esophageal junction, and gastric carcinoma, AMG337 demonstrated an impressive ORR of 62% (8/13) in a subset of patients that harbored high MET amplification, indicating that it is a bonda fide oral MET inhibitor [59] . AMG337 has also been shown in vitro to inhibit migration, invasion, and anchorage-independent growth in gastric cell lines harboring METex14 deletion that have been stimulated by purified HGF [60] . Currently there are no clinical trials investigating the activity of AMG337 against METex14+ NSCLC [45, 53] .
Type II inhibitors
Cabozantinib (Cometriq, XL184)
Cabozantinib (XL184, Cometriq; Elexis) is an oral, type II MET inhibitor, effective against MET. Cabozantinib is multi-targeted, and exhibits activity against other kinases, including vascular endothelial growth factor receptor 2 (VEGFR2), KIT, RET, and AXL. Preclinical studies have demonstrated inhibition of both MET and VEGFR2 phosphorylation, and dose-dependent inhibition of tumor growth in a variety of mouse models, including lung [61] .
Cabozantinib was approved for medullary thyroid cancer in 2012 [62] . Cabozantinib demonstrated modest single-agent activity in a phase 2 trial in patients with metastatic NSCLC (ORR 10%) [63] . In patients with EGFR-mutated NSCLC with resistance to EGFR TKIs, clinical activity was observed following treatment with cabozantinib and erlotinib; however, it should be noted that MET amplification was not detected in the study population [64] . A recent publication described a patient with lung adenocarcinoma with EGFR+/MET amplification who developed a new mutation in MET (D1228V) after progression on savolitinib and osimertinib, and subsequently responded to treatment with cabozantinib and erlotinib [65] . One case series reported a METex14+ NSCLC patient with concurrent MET amplification who achieved a complete response to cabozantinib [21] . Currently there is an investigatorinitiated, single institution phase 2 study focusing on patients with MET-mutated NSCLC, among other actionable driver mutations, in NSCLC (Table 2 ) [45] .
Glesatinib (MGCD265)
Glesatinib (MGCD265; Mirati Therapeutics) is a type II oral inhibitor, with activity against MET, VEGFR1/2/3, RON, and TIE-2. Preclinical antitumor activity was demonstrated in NSCLC xenograft models, including in an EGFR TKI-resistant model, when combined with erlotinib [66] . Subsequent studies in a gastric cancer xenograft model revealed that, in addition to the typically reported cellular activities, glesatinib in combination with erlotinib disrupted the glycolysis pathway, suggesting a novel mechanism of action for this drug [67] .
In an ongoing phase 1 study in patients with MET+ or AXL-rearranged advanced solid tumors, glesatinib demonstrated preliminary single-agent activity, with all three patients with MET dysregulated NSCLC (two with METex14 alterations and one with increased GCN) showing significant tumor regression at the first assessment [68] . A phase 2 study is currently recruiting patients with MET-dysregulated (mutated or amplified) advanced or metastatic NSCLC (Table 2) [69].
Merestinib (LY2801653)
Merestinib (Lilly, Inc) is a multi-targeted TKI that can inhibit MET, RON, AXL, MER receptor tyrosine kinase (MERTK), TIE-2, TIE-1, ROS1, and discoidin domain receptor tyrosine kinase 1 (DDR1) [70] . The in vitro IC 50 of merestinib against MET is 4.7 nM and the cellbased IC 50 is 35-52 nM, depending on the cell lines utilized [70] . Treatment with merestinib inhibited the constitutive activation of MET signaling and resulted in inhibition of NCI-H441 cell proliferation, anchorage-independent growth, migration, and invasion. Additionally, merestinib inhibited orthopedic H441 primary tumor growth or metastasis and resulted in longer survival of mice bearing the H441 orthopedic transplant compared with vehicle injection [71] . In the H1993 NSCLC cell line, which harbors MET amplification and also overexpression of RON, merestinib was superior to crizotinib in terms of cellular growth inhibitory activity (9.28 nM versus 45.4 nM, respectively) [72] .
A phase 2 study has recently been initiated that includes a cohort of patients with METex14-mutated NSCLC (Table 2) [45].
Clinicopathologic characteristics of METex14+ NSCLC patients (the Unknown)
Although there have been many reports on the clinicopathologic characteristics of METex14+ NSCLC patients (Table 1) , much remains to be discovered. Firstly, the prevalence of brain metastasis at the time of diagnosis of METex14+ NSCLC patients is unknown. Even more importantly, the prevalence of central nervous system (CNS) progression from MET TKIs is unknown. If the natural history of METex14+ NSCLC disease mirrors that of ALK+ NSCLC [73] , then progression in the CNS will be a significant therapeutic challenge to MET-targeted therapy, and the ability of MET TKIs to penetrate the CNS will be of paramount importance. Preliminary CNS activity of cabozantinib in a METex14+ NSCLC patient has been observed [74] . Secondly, while it is generally established that MET amplification is a poor prognostic factor in NSCLC [73, [75] [76] [77] , the prognostic significance of METex14 alterations in NSCLC is unknown. Thirdly, Schrock and colleagues have demonstrated that tumors with METex14+ alterations with concurrent MET amplification harbored a significantly higher total mutational burden (TMB) [31] . It remains to be determined whether concurrent MET amplification modulates the response to MET TKIs, as this molecular alteration could affect the efficacy of MET TKIs if it is not properly accounted for. Fourthly, Schrock and colleagues also reported a high incidence of concurrent MDM2 amplification [31] . MDM2 encodes an E3 ubiquitin-protein ligase, and whether MDM2 amplification is a response to the absence of an E3 ubiquitin-protein ligase binding site in the METex14 altered protein, or whether it has another role in METex14+ NSCLC, such as resistance to TKIs, remains to be investigated [78] .
Potential strategies to overcome resistance to MET TKIs (the Inevitable)
Resistance to targeted therapy with a single agent TKI invariably occurs (Fig. 2) . The tight binding of the MET TKIs to the ATP-pocket of MET RTK is facilitated by several hydrophobic interactions at several specific amino acids. In vitro mutagenesis assays with MET TKIs in MET-dependent tumors have identified several predominant resistance mutations against type I inhibitors (Y1230, D1228) [79, 80] and several minor resistance mutations (F1200, V1155) [80] . Indeed, acquired crizotinib resistance mutations, MET D1228N and MET Y1230C, have recently been described in patients with METex14+ NSCLC refractory to crizotinib [81, 82] . Residue D1228 is important to stabilize the orientation of the activation loop in the inactive autoinhibitory conformation of MET, and D1228N muta- 
Switching from type I to type II inhibitors or vice versa for acquired resistance mutations
Given that type I inhibitors require stacking with Y1230 to bind to MET, mutations in Y1230 abolish the binding of type I MET TKIs. For example, the IC 50 of AMG337 against wild-type MET is 1 nM, but the IC 50s against Y1230H and D1228H are 1077 nM and >4000 nM, respectively [58] . Switching from a type I MET TKI to type II MET TKI may overcome this group of resistance mutations; for example, the IC 50s of merestinib against wild-type Y1230C and D1228N MET are 42 nM, 54 nM, and 111 nM, respectively [70] . Clinical trials that allow switching from type I inhibitors (the predominant TKIs in clinical trial) to type II inhibitors will have to be conducted to thoroughly test this hypothesis, but data from one case study is supportive: a patient with lung adenocarcinoma and a D1228H point mutation responded to cabozantinib after progression on savolitinib [65] . Additionally, the ability to detect the acquired resistance mechanism will be important to ensure the success of these "noncross resistant" trials.
"Total" MET signaling axis blockade
An important difference between RTK-rearranged NSCLC and METex14+ NSCLC is that the ligand binding domain of METex14+ NSCLC is intact, and ligand-mediated activation of the MET receptor protein is ongoing. Therefore, one potential mechanism of resistance is the upregulation of HGF, which can potentially increase the percentage of MET receptors in the active (phosphorylated) conformation, increasing the Michaelis constant (K m , the concentration of substrate that permits the enzyme to achieve half the V max , the maximum rate of the reaction) of ATP inhibitors, and essentially abolishing the binding of type II inhibitors to MET [37] . Thus, to overcome or delay the emergence of resistance to MET TKIs, it may be advisable to combine MET TKIs with antibodies against HGF, or antibodies that block ligand binding to or dimerization of the MET receptor. This is similar to the design rationale of the 4th generation EGFR TKIs [84] .
5.2.1. Combination with antibodies against MET 5.2.1.1. Emibetuzumab (LY2875358). Emibetuzumab (LY2875358; Lilly) is a humanized, bivalent, IgG4 mAb, designed to block both ligand-dependent and ligand-independent MET signaling (binding affinity 0.8 pM) [85] . It induces internalization and degradation of MET, inhibiting proliferation of tumor cells with MET amplification and providing antitumor activity in xenograft models of NSCLC [85] . Preliminary, but limited, single-agent clinical activity was observed in a phase I trial in patients with MET+ (IHC ≥2+) solid tumors, including NSCLC [86] .
5.2.1.2. ABT-700. ABT-700 (hz224G11; AbbVie) is a humanized, IgG1 mAb with nanomolar affinity for human MET. It exhibited preclinical activity in cell lines, inhibiting HGF binding and subsequent MET phosphorylation, and also induced apoptosis in gastric cancer xenografts [87] . The safety and preliminary efficacy of ABT-700 is currently being investigated in a phase 1 trial in patients with MET dysregulated solid tumors [45] . [88] . In a phase 2 study in Asian patients with NSCLC, ficlatuzumab in combination with gefitinib showed preliminary efficacy in the EGFR-mutated, low-MET population [89] . Clinical development is ongoing, including a proof-of-concept study (FOCAL) of ficlatuzumab in combination with erlotinib in patients with EGFRmutant NSCLC selected using BDX004, a serum-based proteomic companion diagnostic test [45, 90] .
5.2.3.
Combination with antibody-drug conjugates 5.2.3.1. ABBV-399. Antibody-drug conjugates represent a novel class of drugs that utilize targeted antibodies to deliver cytotoxic agents directly to tumor cells. ABBV-399 (AbbVie) is a first-in-class conjugate of a MET Ab, ABT-700, and an antimicrotubule agent, monomethyl auristatin E. Preliminary analysis from a phase 1 study in patients (N = 45) with metastatic solid tumors that included an expansion cohort of 10 patients with MET+ (IHC ≥2+) NSCLC reported promising antitumor activity in these MET+ patients (30% response) [91] . Given that the major sequela of METex14 deletion is persistence of the MET protein, this molecular subgroup of NSCLC is a good target for ABBV-399.
Combination with immunotherapy
Immunotherapy utilizing anti-programmed cell death protein 1 (anti-PD-1) antibodies has been approved in the US for platinumrefractory NSCLC based on significant overall survival benefit over single-agent docetaxel [92] [93] [94] . Rivzi and colleagues have reported that mutational load is closely related to response to pembrolizumab [95] . Tumor mutational load can serve as a surrogate marker for the reservoir of neoantigens, with higher mutation load corresponding to higher reservoir of neoantigens. The average TMB in METex14+ NSCLC patients was 6.9 mutations/Mb (range 0-197.9), which is slightly lower than the overall average of 10.7 mutations/Mb for all lung cancer cases [31] , but higher than the average TMB for EGFR-mutated (mean, 4.5) and ALK+ NSCLC (mean, 2.8) patients [96] . Gainor and colleagues reported that for EGFR-mutated and ALK+ NSCLC patients, the incidence of co-expression of PD-L1 is low, as is response to anti-PD-L1/PD-1 therapy [97] . While the expression level of PD-L1 among patients with METex14+ NSCLC is currently unknown, a higher average TMB among METex14+ NSCLC patients than EGFR+ or ALK+ NSCLC patients, especially among the MET amplified subgroup, would suggest that the combination of MET TKIs and immunotherapy may be successful.
Conclusions
Only two years ago, amplification of MET in NSCLC was postulated to be the target that would lead to the eventual regulatory approval of MET TKIs [98] . As the incidence of true de novo MET amplification remains low (0.8%) and the incidence of MET amplification as a resistance mechanism to EGFR TKIs is only 5%, the road to regulatory approval of MET TKIs seemed uncertain [98] . There has since been renewed interest in METex14 alterations in NSCLC, with the prevalence closer to 3%, and reports of responses to MET TKIs. Dedicated clinical trials with MET TKIs in METex14+ NSCLC are underway, which are likely to lead to the eventual approvals of MET TKIs.
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